InMed Pharmaceuticals (INM) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
InMed Pharmaceuticals announced the results of their 2024 Annual General Meeting, where shareholders approved the election of four directors and the appointment of CBIZ LLP as their auditors for the coming year. However, the election of Ms. Janet Grove was withheld, prompting her resignation offer, which is under consideration. The company is focused on developing drug candidates for diseases with high unmet needs.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.